title: Cancer vaccines: identification of biomarkers predictive of clinical efficacy.
abstract: Personalized medicine is playing an increasingly important role in the treatment of patients living with cancer. This landmark shift has been driven in part by statistics emerging from the "one size fits all" approach to the treatment of cancer patients. Some reports suggest that only a minority of individuals actually benefit from treatment and adverse effects of medications remain a major cause of hospitalization, morbidities and deaths. Although the side-effect profile of most immunotherapy treatment modalities is usually fairly benign, there is no reason to believe that immunotherapy is any different from other oncology therapies in that some patients are likely to receive more benefit than others. Indeed, the fact that generation of the therapeutic modality requires translation through multiple complex biological processes for an immunotherapy product to be effective may mean that such approaches require an even better understanding of the patient being treated. Furthermore, the very low success rate of cancer immunotherapy approaches to deliver benefit to patients demands a more detailed understanding of who will benefit and why. The identification of biomarkers predictive of treatment benefit is one route to improve the success rate of cancer vaccines.
authors.affiliation: Oxford BioMedica (UK) Ltd.; The Medawar Centre; Oxford, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Harrop
mesh_terms: D015415:Biomarkers / Q000032:analysis*; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*
chemical_list: D015415:Biomarkers; D019496:Cancer Vaccines
keywords: cancer; immune response; predictive biomarker; therapeutic vaccine; tumor antigen
references.citation: Cancer Immunol Immunother. 2009 Oct;58(10):1657-67
references.pmid: 19221742
references.citation: Clin Cancer Res. 2010 Nov 15;16(22):5539-47
references.pmid: 20881001
references.citation: J Immunother. 2008 Jul-Aug;31(6):577-85
references.pmid: 18528296
references.citation: Cancer Immunol Immunother. 2013 Jan;62(1):137-47
references.pmid: 22865266
references.citation: Clin Cancer Res. 2010 Jul 1;16(13):3299-318
references.pmid: 20501613
references.citation: Clin Cancer Res. 2008 Nov 15;14(22):7504-10
references.pmid: 19010868
references.citation: J Immunother. 2009 Sep;32(7):765-72
references.pmid: 19561532
references.citation: Lancet Oncol. 2011 Nov;12(12):1125-33
references.pmid: 22019520
references.citation: Clin Cancer Res. 2011 May 15;17(10):3064-76
references.pmid: 21558394
references.citation: J Transl Med. 2009 Jan 07;7:2
references.pmid: 19128501
references.citation: Immunity. 2012 Jul 27;37(1):1-2
references.pmid: 22840835
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3416-24
references.pmid: 16740766
references.citation: Cancer Immunol Immunother. 2008 Jul;57(7):977-86
references.pmid: 18060404
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4487-94
references.pmid: 17671134
references.citation: J Transl Med. 2011 Dec 14;9:214
references.pmid: 22168571
references.citation: J Immunother. 2009 May;32(4):424-9
references.pmid: 19342962